[ad_1]
SAN FRANCISCO and SHANGHAI, September 6, 2018 / PRNewswire / – Today, Driver, a global technology platform that connects cancer patients to the best treatments, launches into United States and China. The Driver platform allows any patient, anywhere in the world, to access treatment options in an unprecedented network of cancer centers without leaving his home.
Although there has never been more cancer treatments, patients and their doctors are unaware of all these options and, as a result, patients are not living as long as they could existing treatments. The Driver platform eliminates this gap, allowing patients to access the best treatments around the world.
The US National Cancer Institute and the National Cancer Center of China are the founding members of the global Driver Network. To date, more than thirty leading cancer centers include the driver network, including the Cleveland Clinic, the Mayo Clinic, Massachusetts General Hospital, University of California, San Francisco, University of California at Los Angeles, Duc, University of North Carolina, and Emory.
"In a world of Amazon, Airbnb and other technology platforms that have revolutionized our ability to access products and services, consumers deserve the same transformative power from these next-generation markets. when they are facing cancer and require treatment, "said Dr. William R. PolkinghornCo-founder and CEO of Driver and former radiation oncologist at the Memorial Sloan Kettering Cancer Center.
"By 2018, cancer patients are still required to enter a specialty hospital and interact with a doctor only to find out their treatment options," said Dr. Petros Giannikopoulos, Co-founder and President of Driver. "It's a problem because different hospitals have different treatments, different doctors have different knowledge and, therefore, too many patients are not getting the best treatment available."
The driver's platform occupies the empty space between the patient and the hospital. Patients join the platform using a mobile app, which gives the driver the consent to acquire the necessary information (medical records and tumor samples) connect them to their best treatment options. The patient receives treatment options for standards of care based on guidelines and clinical trials available through the network of drivers. Patients have the opportunity to review their video treatment options with an expert oncologist and then select a hospital in the driver network for further evaluation. The driver organizes the appointment at the hospital of his choice and delivers his records and other information necessary for the evaluation.
"While great strides have been made in personalizing cancer treatments in recent years, many patients are unaware of all their options," said Dr. Keith Flaherty, Director of the Henri and Belinda Termeer Center for Targeted Therapies at Massachusetts General Hospital, member of the driver network. "The driver's approach could revolutionize the way treatment options are presented to patients at the essential points of their care."
To extract information from patient records and tumor samples, the Driver platform utilizes a combination of proprietary software and hardware, including two automated clinical labs, San Francisco and a second in Shantou, China. Driver valid its treatment matching software in collaboration with the US National Cancer Institute, the results of which were presented at the 2018 annual meeting of the American Society of Clinical Oncology. In addition, both American pilots and China The labs are certified by the Clinical Laboratory Improvement Amendments (CLIA) of the Centers for Medicare & Medicaid Services (CMS) and accredited by the College of American Pathologists (CAP), the benchmark for laboratory accreditation.
The principal investor of the driver is Horizons Ventures (Li Ka Shing), with whom Driver has been associated since its creation to build its platform China in parallel to United States. From driver software tools to its automated lab, to its cloud-independent software architecture, Driver processes patient information China identical to the information of the patient in United States. With headquarters in both Shanghai and San Francisco, Driver is the first technology platform to co-launch United States and China.
"We are in the midst of a revolution in our understanding of cancer, which has resulted in an unprecedented number of new treatment strategies, and this revolution is taking place around the world, and increasingly in the world. China"said Dr. Alan Ashworth, President of the UCSF's Helen Diller Family Cancer Treatment Center and a member of the Scientific Advisory Committee of Driver. "Yet many patients and doctors are unaware of all options.A new technology platform that, by definition, allows patients to access all their options must be comprehensive to help not only patients today But also to accelerate progress in clinical research for future patients all over the world. "
Driver. The cure for cancer treatment. For more information, visithe https://driver.xyz/ or follow us on social networks: Facebook, Twitter, Instagram, LinkedIn.
About the driver
Situated at San Francisco and ShanghaiDriver is a technology platform that connects cancer patients to treatments and knowledge around the world to improve their lives. Through a patient app and a doctor app, the Driver platform allows all cancer patients, regardless of where they live, to access options from the global network of cancer centers. of Driver. The driver network includes more than 30 of the world's leading cancer centers, including its founding members, the US National Cancer Institute and the National Cancer Center of China. Other members of the driver network include the Cleveland Clinic, the Mayo Clinic, Massachusetts General Hospital, University of California at San Francisco, University of California at Los Angeles, Duc, University of North Carolina, and Emory. Driver was founded in 2015 by two doctors, Dr. William R. Polkinghorn and Dr. Petros Giannikopoulos, and the principal investor of Driver is Horizons Ventures (Li Ka Shing).
Global network of drivers
- Samuel Oschin Comprehensive Cancer Institute of Cedars-Sinai
- Chinese National Cancer Center
- City of Hope Cancer Center
- Cleveland Cancer Center
- University of Colorado Cancer Center
- Columbia University Medical Center
- Weill Cornell Medicine
- Duke Cancer Institute
- Emory Winship Cancer Institute
- Futang Pediatric Development Research Center and Beijing Children's Hospital
- Virginia G. Piper Cancer Center at HonorHealth
- Huntsman Cancer Institute
- Howard University Cancer Center
- Mayo Clinic
- Mayo Clinic – Jacksonville
- Mayo Clinic – Phoenix
- Massachusetts General Hospital
- Miami Cancer Institute
- University of Michigan Rogel Cancer Center
- Mount Sinai Cancer Institute Tisch
- NYU Langone Laura and Isaac Perlmutter Cancer Center
- National Cancer Institute, part of the National Institutes of Health in United States Department of Health and Social Services
- Ochsner Medical Center
- University of Health and Sciences of Oregon
- University of Rochester Wilmot Cancer Institute Medical Center
- Stanford Cancer Institute
- Thomas Jefferson University Sidney Kimmel Cancer Center
- University of California at Los Angeles Jonsson Comprehensive Cancer Center and TRIO – United States
- University of California, San Francisco Comprehensive Cancer Center Helen Diller Family
- Seidman Cancer Center University Hospitals
- University of North Carolina Lineberger Cancer Center
- University of Virginia Emily Couric Cancer Center
- University of Pittsburgh Hillman Cancer Center Medical Center
- University of Texas South Carolina Cancer Center Harold C. Simmons
- National Cancer Center of Singapore
Biographies of the co-founders
William R. Polkinghorn, MD is a medical scientist, formerly at Memorial Sloan's Kettering Cancer Center, where his translational research and radiation-oncology practice focused on improving the treatment of high-risk prostate cancer. Dr. Polkinghorn earned an MBA from University of Oxford like a Rhodes learned, received his MD from Harvard Medical School, where he was a member of the Howard Hughes Medical Institute, and attended clinical training at Massachusetts General Hospital and Memorial Sloan Kettering Cancer Center. He then completed his postdoctoral internship at Dr. Charles L. Sawyers. For his research, Dr. Polkinghorn has received the Prostate Cancer Foundation's Creativity Award, the ASCO Young Investigator Award and the Charles A. Dana Scholarship.
Petros Giannikopoulos, MD is a pediatric pathologist, molecular and anatomical genetics certified by the board of directors. Dr. Giannikopoulos obtained his doctorate in medicine Harvard Medical School, where he was a member of the Howard Hughes Medical Institute. He then completed his training in anatomical pathology and pathology at UCSF, after which he completed internships in pediatric pathology at Baylor College of Medicine and molecular genetic pathology at Harvard. The Harvard Molecular Genetics Scholarship included training in all diagnostic laboratories affiliated with Harvard, including Brigham and Women's Hospital, the Beth Israel Deaconess Medical Center, Massachusetts General Hospital, Boston Children's Hospital and Laboratory of Molecular Medicine. During his fellowship, Dr. Giannikopoulos also pursued postdoctoral research on next generation cancer genomics at the Broad Institute.
Disclaimer:
The information mentioned above has been prepared by Driver and only reflects the opinion of Driver. Nothing in this statement shall be construed to imply endorsement or endorsement by the pilot, or any of its products, by the regents of University of Californiaits leaders, agents and employees.
For media inquiries, contact:
Sun Sachs
323-822-9300 | 212-691-2800
SOURCE Driver
Related Links
https://driver.xyz/
[ad_2]
Source link
